Does Rallies show Form 4 insider transactions for NRXS?

Yes. Rallies tracks NRXS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NRXS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NRXS. It does not provide personalized investment advice.

NRXS (Neuraxis, Inc.) Stock Analysis - Insider Trades

Neuraxis, Inc. (NRXS) is a publicly traded Healthcare sector company. As of May 21, 2026, NRXS trades at $7.18 with a market cap of $91.77M and a P/E ratio of -7.64. NRXS moved -0.69% today. Year to date, NRXS is +64.40%; over the trailing twelve months it is +81.70%. Its 52-week range spans $1.33 to $9.33. Analyst consensus is buy with an average price target of $0.00. Rallies surfaces NRXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NRXS stock inside the company?

Recent NRXS insider activity includes Henrichs Timothy Robert bought 7.59K, Carrico Thomas Joeseph bought 667, Carrico Brian Allen bought 8.06K, Aharon Gil bought 286.14K, and MASIMO CORP sold 531.55K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NRXS Key Metrics

Key financial metrics for NRXS
Metric	Value
Price	$7.18
Market Cap	$91.77M
P/E Ratio	-7.64
EPS	$-0.95
Dividend Yield	0.00%
52-Week High	$9.33
52-Week Low	$1.33
Volume	410
Avg Volume	0
Revenue (TTM)	$3.57M
Net Income	$-7.80M
Gross Margin	84.23%

Recent NRXS Insider Trades

Henrichs Timothy Robert bought 7.59K (~$14.88K) on Apr 1, 2026.
Carrico Thomas Joeseph bought 667 (~$1.31K) on Apr 1, 2026.
Carrico Brian Allen bought 8.06K (~$15.80K) on Apr 1, 2026.
Aharon Gil bought 286.14K (~$1.01M) on Dec 23, 2025.
MASIMO CORP sold 531.55K (~$1.20M) on Jul 1, 2025.

Latest NRXS News

Neuraxis Q1 Revenue Climbs While Reimbursement Hurdles Delay Cash Conversion — May 13, 2026
NeurAxis Q1 Revenues Surge 80% to $1.6M, Gross Margin Hits 86.4% — May 12, 2026
NeurAxis Adds 1.25M Covered Lives with Four New Insurer Policies — Apr 22, 2026
NeurAxis Declares 510,605-Share Dividend for Series B at $2.38 Conversion — Apr 10, 2026
Neuraxis Inc Q4 Revenue Up 27% While Gross Margin Dips to 85.4% — Mar 19, 2026

NRXS Analyst Consensus

1 analysts cover NRXS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $0.00.

Common questions about NRXS

Who is trading NRXS stock inside the company?: Recent NRXS insider activity includes Henrichs Timothy Robert bought 7.59K, Carrico Thomas Joeseph bought 667, Carrico Brian Allen bought 8.06K, Aharon Gil bought 286.14K, and MASIMO CORP sold 531.55K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NRXS?: Yes. Rallies tracks NRXS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NRXS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NRXS. It does not provide personalized investment advice.